Trial Profile
A Phase 2, Randomized, Double-Blind, Multicenter Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Entinostat (Primary) ; Fulvestrant
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Syndax Pharmaceuticals
- 07 Oct 2014 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 18 Apr 2014 New trial record